
News|Articles|December 8, 2010
ASH 2010 Homepage Header
Advertisement
Oncology NEWS International reports on critical information from the American Society of Hematology's 52nd annual meeting.
- Rituximab instead of ‘watch and wait’ policy in asymptomatic follicular lymphoma causes controversy
- Ofatumumab generates high response rates in refractory CLL
- Industry update: Early-stage trials establish pathways for new treatment agents
- More Coverage from ASH 2010
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Accepts Topical Gel sNDA for Superficial Basal Cell Carcinoma
2
Advances in Immunotherapy for Breast Cancer
3
Phase 2b Prostate Cancer Study Receives FDA Clearance in High-Risk Groups
4
Tandem 2026: Key Advances in Cellular Therapy and Transplantation
5





































